|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DACT3 |
Gene summary for DACT3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DACT3 | Gene ID | 147906 |
| Gene name | dishevelled binding antagonist of beta catenin 3 | |
| Gene Alias | DAPPER3 | |
| Cytomap | 19q13.32 | |
| Gene Type | protein-coding | GO ID | GO:0001558 | UniProtAcc | A0A0C4DFP1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 147906 | DACT3 | ATC12 | Human | Thyroid | ATC | 5.88e-09 | 2.04e-01 | 0.34 |
| 147906 | DACT3 | ATC13 | Human | Thyroid | ATC | 1.04e-27 | 5.32e-01 | 0.34 |
| 147906 | DACT3 | ATC4 | Human | Thyroid | ATC | 1.14e-11 | 2.62e-01 | 0.34 |
| 147906 | DACT3 | ATC5 | Human | Thyroid | ATC | 6.62e-35 | 5.79e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001605525 | Thyroid | ATC | Wnt signaling pathway | 234/6293 | 444/18723 | 4.64e-17 | 4.31e-15 | 234 |
| GO:019873825 | Thyroid | ATC | cell-cell signaling by wnt | 234/6293 | 446/18723 | 9.26e-17 | 8.25e-15 | 234 |
| GO:003011125 | Thyroid | ATC | regulation of Wnt signaling pathway | 177/6293 | 328/18723 | 1.83e-14 | 1.05e-12 | 177 |
| GO:001604927 | Thyroid | ATC | cell growth | 241/6293 | 482/18723 | 4.27e-14 | 2.35e-12 | 241 |
| GO:006082825 | Thyroid | ATC | regulation of canonical Wnt signaling pathway | 134/6293 | 253/18723 | 1.49e-10 | 4.56e-09 | 134 |
| GO:000155826 | Thyroid | ATC | regulation of cell growth | 201/6293 | 414/18723 | 1.57e-10 | 4.76e-09 | 201 |
| GO:006007025 | Thyroid | ATC | canonical Wnt signaling pathway | 154/6293 | 303/18723 | 3.68e-10 | 1.02e-08 | 154 |
| GO:000183722 | Thyroid | ATC | epithelial to mesenchymal transition | 87/6293 | 157/18723 | 1.50e-08 | 3.06e-07 | 87 |
| GO:004876221 | Thyroid | ATC | mesenchymal cell differentiation | 116/6293 | 236/18723 | 5.08e-07 | 7.30e-06 | 116 |
| GO:006048521 | Thyroid | ATC | mesenchyme development | 136/6293 | 291/18723 | 2.04e-06 | 2.43e-05 | 136 |
| GO:003017815 | Thyroid | ATC | negative regulation of Wnt signaling pathway | 85/6293 | 170/18723 | 6.94e-06 | 7.16e-05 | 85 |
| GO:004592622 | Thyroid | ATC | negative regulation of growth | 115/6293 | 249/18723 | 2.34e-05 | 2.06e-04 | 115 |
| GO:003030813 | Thyroid | ATC | negative regulation of cell growth | 90/6293 | 188/18723 | 3.35e-05 | 2.78e-04 | 90 |
| GO:001071712 | Thyroid | ATC | regulation of epithelial to mesenchymal transition | 53/6293 | 99/18723 | 3.42e-05 | 2.82e-04 | 53 |
| GO:009009014 | Thyroid | ATC | negative regulation of canonical Wnt signaling pathway | 66/6293 | 137/18723 | 2.82e-04 | 1.80e-03 | 66 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DACT3 | SNV | Missense_Mutation | c.1861N>T | p.Gly621Cys | p.G621C | Q96B18 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A09E-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | |
| DACT3 | insertion | Frame_Shift_Ins | novel | c.1620_1621insAAGCGGCCCTCAGCCGGGCT | p.Val541LysfsTer70 | p.V541Kfs*70 | Q96B18 | protein_coding | TCGA-A8-A081-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| DACT3 | insertion | In_Frame_Ins | novel | c.1774_1775insAACCAC | p.Ala592delinsGluProPro | p.A592delinsEPP | Q96B18 | protein_coding | TCGA-A8-A08J-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| DACT3 | insertion | Frame_Shift_Ins | novel | c.1772_1773insCG | p.Ala592ValfsTer13 | p.A592Vfs*13 | Q96B18 | protein_coding | TCGA-A8-A08J-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| DACT3 | insertion | Frame_Shift_Ins | novel | c.1620_1621insTCAGCCGGGCT | p.Val541SerfsTer67 | p.V541Sfs*67 | Q96B18 | protein_coding | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | ||
| DACT3 | SNV | Missense_Mutation | novel | c.374N>A | p.Gly125Glu | p.G125E | Q96B18 | protein_coding | tolerated(0.09) | benign(0.139) | TCGA-VS-A8EK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| DACT3 | SNV | Missense_Mutation | c.1751N>T | p.Ala584Val | p.A584V | Q96B18 | protein_coding | tolerated(0.18) | benign(0.401) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DACT3 | SNV | Missense_Mutation | novel | c.358G>T | p.Asp120Tyr | p.D120Y | Q96B18 | protein_coding | tolerated(0.09) | probably_damaging(0.937) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| DACT3 | SNV | Missense_Mutation | c.1553N>T | p.Ala518Val | p.A518V | Q96B18 | protein_coding | tolerated(0.56) | possibly_damaging(0.566) | TCGA-AY-A69D-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| DACT3 | SNV | Missense_Mutation | c.1649C>T | p.Ser550Leu | p.S550L | Q96B18 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |